PMC:7033706 / 5512-6146 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"135","span":{"begin":302,"end":306},"obj":"Gene"},{"id":"136","span":{"begin":47,"end":50},"obj":"Species"},{"id":"137","span":{"begin":120,"end":125},"obj":"Species"},{"id":"138","span":{"begin":126,"end":139},"obj":"Species"},{"id":"139","span":{"begin":151,"end":159},"obj":"Species"},{"id":"140","span":{"begin":164,"end":172},"obj":"Species"},{"id":"141","span":{"begin":191,"end":195},"obj":"Species"},{"id":"142","span":{"begin":296,"end":301},"obj":"Species"},{"id":"143","span":{"begin":307,"end":322},"obj":"Species"},{"id":"144","span":{"begin":577,"end":586},"obj":"Species"},{"id":"145","span":{"begin":606,"end":619},"obj":"Species"},{"id":"146","span":{"begin":102,"end":111},"obj":"Disease"},{"id":"147","span":{"begin":333,"end":346},"obj":"Disease"},{"id":"148","span":{"begin":417,"end":436},"obj":"Disease"},{"id":"149","span":{"begin":564,"end":573},"obj":"Disease"}],"attributes":[{"id":"A135","pred":"tao:has_database_id","subj":"135","obj":"Gene:1803"},{"id":"A136","pred":"tao:has_database_id","subj":"136","obj":"Tax:11118"},{"id":"A137","pred":"tao:has_database_id","subj":"137","obj":"Tax:9606"},{"id":"A138","pred":"tao:has_database_id","subj":"138","obj":"Tax:11118"},{"id":"A139","pred":"tao:has_database_id","subj":"139","obj":"Tax:694009"},{"id":"A140","pred":"tao:has_database_id","subj":"140","obj":"Tax:1335626"},{"id":"A141","pred":"tao:has_database_id","subj":"141","obj":"Tax:11118"},{"id":"A142","pred":"tao:has_database_id","subj":"142","obj":"Tax:9606"},{"id":"A143","pred":"tao:has_database_id","subj":"143","obj":"Tax:10090"},{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"Tax:2697049"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"Tax:11118"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"MESH:D007239"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"MESH:D018352"},{"id":"A148","pred":"tao:has_database_id","subj":"148","obj":"MESH:C000657245"},{"id":"A149","pred":"tao:has_database_id","subj":"149","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"We have recently designed and engineered a pan-CoV fusion inhibitor, EK1 peptide, which could inhibit infection of five human coronaviruses, including SARS-CoV and MERS-CoV, and three bat-SL-CoVs [7]. Intranasal application of EK1 peptide before or after viral challenge, EK1 peptide can protect human DPP4-transgenic mice from MERS-CoV infection, suggesting its potential prophylactic and therapeutic effect against 2019-nCoV infection. Once confirmed, we will develop EK1 peptide as a t prophylactic or therapeutic for intranasal application to prevent or treat infection by 2019-nCoV and other emerging coronaviruses in the future."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T20","span":{"begin":102,"end":111},"obj":"Disease"},{"id":"T21","span":{"begin":151,"end":159},"obj":"Disease"},{"id":"T22","span":{"begin":337,"end":346},"obj":"Disease"},{"id":"T23","span":{"begin":417,"end":436},"obj":"Disease"},{"id":"T24","span":{"begin":427,"end":436},"obj":"Disease"},{"id":"T25","span":{"begin":564,"end":573},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"We have recently designed and engineered a pan-CoV fusion inhibitor, EK1 peptide, which could inhibit infection of five human coronaviruses, including SARS-CoV and MERS-CoV, and three bat-SL-CoVs [7]. Intranasal application of EK1 peptide before or after viral challenge, EK1 peptide can protect human DPP4-transgenic mice from MERS-CoV infection, suggesting its potential prophylactic and therapeutic effect against 2019-nCoV infection. Once confirmed, we will develop EK1 peptide as a t prophylactic or therapeutic for intranasal application to prevent or treat infection by 2019-nCoV and other emerging coronaviruses in the future."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T77","span":{"begin":41,"end":42},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T78","span":{"begin":43,"end":46},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9596"},{"id":"T79","span":{"begin":73,"end":80},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T80","span":{"begin":120,"end":125},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T81","span":{"begin":184,"end":187},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9397"},{"id":"T82","span":{"begin":231,"end":238},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T83","span":{"begin":276,"end":283},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T84","span":{"begin":296,"end":301},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T85","span":{"begin":474,"end":481},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T86","span":{"begin":485,"end":486},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"We have recently designed and engineered a pan-CoV fusion inhibitor, EK1 peptide, which could inhibit infection of five human coronaviruses, including SARS-CoV and MERS-CoV, and three bat-SL-CoVs [7]. Intranasal application of EK1 peptide before or after viral challenge, EK1 peptide can protect human DPP4-transgenic mice from MERS-CoV infection, suggesting its potential prophylactic and therapeutic effect against 2019-nCoV infection. Once confirmed, we will develop EK1 peptide as a t prophylactic or therapeutic for intranasal application to prevent or treat infection by 2019-nCoV and other emerging coronaviruses in the future."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T38","span":{"begin":58,"end":67},"obj":"Chemical"},{"id":"T39","span":{"begin":73,"end":80},"obj":"Chemical"},{"id":"T40","span":{"begin":188,"end":190},"obj":"Chemical"},{"id":"T41","span":{"begin":212,"end":223},"obj":"Chemical"},{"id":"T42","span":{"begin":231,"end":238},"obj":"Chemical"},{"id":"T43","span":{"begin":276,"end":283},"obj":"Chemical"},{"id":"T44","span":{"begin":474,"end":481},"obj":"Chemical"},{"id":"T45","span":{"begin":532,"end":543},"obj":"Chemical"}],"attributes":[{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_74815"},{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"}],"text":"We have recently designed and engineered a pan-CoV fusion inhibitor, EK1 peptide, which could inhibit infection of five human coronaviruses, including SARS-CoV and MERS-CoV, and three bat-SL-CoVs [7]. Intranasal application of EK1 peptide before or after viral challenge, EK1 peptide can protect human DPP4-transgenic mice from MERS-CoV infection, suggesting its potential prophylactic and therapeutic effect against 2019-nCoV infection. Once confirmed, we will develop EK1 peptide as a t prophylactic or therapeutic for intranasal application to prevent or treat infection by 2019-nCoV and other emerging coronaviruses in the future."}

{"project":"LitCovid-sentences","denotations":[{"id":"T31","span":{"begin":0,"end":200},"obj":"Sentence"},{"id":"T32","span":{"begin":201,"end":437},"obj":"Sentence"},{"id":"T33","span":{"begin":438,"end":634},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"We have recently designed and engineered a pan-CoV fusion inhibitor, EK1 peptide, which could inhibit infection of five human coronaviruses, including SARS-CoV and MERS-CoV, and three bat-SL-CoVs [7]. Intranasal application of EK1 peptide before or after viral challenge, EK1 peptide can protect human DPP4-transgenic mice from MERS-CoV infection, suggesting its potential prophylactic and therapeutic effect against 2019-nCoV infection. Once confirmed, we will develop EK1 peptide as a t prophylactic or therapeutic for intranasal application to prevent or treat infection by 2019-nCoV and other emerging coronaviruses in the future."}